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Abstract
Background and Aim: Non-alcoholic fatty liver disease (NAFLD) is the most common liver disease in
Western countries. While obesity and diabetes are the hallmarks of NAFLD, it also develops in lean individuals
in the absence of metabolic syndrome, with a prevalence of 7 percent in the U.S. and 25-30 percent in some
Asian countries. NAFLD represents the spectrum of liver disease, starting with excess liver fat accumulation
(NAFL) that can progress to nonalcoholic steatohepatitis (NASH), cirrhosis and ultimately hepatocellular
carcinoma (HCC). To date, the pathogenesis of lean NASH-HCC is poorly understood and a mouse model is
lacking. We aimed to develop a mouse model of lean NASH-HCC using a choline deficient and high
trans-fat/sucrose/cholesterol diet to enable better understanding of its molecular pathogenesis.
Methods: C57BL/6N mice were fed this diet starting at 4 weeks of age for 52 weeks and were compared to
mice fed an isocaloric low fat control diet for the same duration. C57BL/6N mice were chosen instead of the
C57BL/6J mice due to the high susceptibility of C57BL/6J mice to diet-induced obesity. The plasma and tumor
fatty acid profile of these mice was also investigated.
Results: Nearly 61% of the mice developed lean NASH-HCC. These mice showed reduction of plasma
polyunsaturated fatty acids (PUFAs) (linolenic acids (D and Ǆ, ǚ-3 and ǚ-6, respectively), eicosapentanoic acid
(ǚ-3), docosahexanoic acid (ǚ-3), and linoleic acid (ǚ-6)) and increasing levels over time in mice with
pre-malignant lesions.
Conclusions: We developed a novel high penetrance diet-induced lean NASH-HCC mouse model. Plasma
PUFA levels were reduced with tumor progression in parallel with reduced expression of genes controlling
desaturase expression suggesting their potential use as biomarkers for lean NASH-HCC progression as well as
chemopreventive molecules.
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Introduction
NAFLD has a 24 percent prevalence globally and
is predicted to be the leading cause for liver
transplantation in the United States by 2030 [1,2]. It
represents the spectrum of liver disease, starting with
excess liver fat accumulation (NAFL) that can
progress to nonalcoholic steatohepatitis (NASH),
cirrhosis and ultimately hepatocellular carcinoma
(HCC) [3]. NAFLD accounts for an increasing number

of HCCs [4,5,6].
While obesity, diabetes, and genetic predisposition are the hallmarks of NAFLD, it also
develops in lean individuals in the absence of
metabolic syndrome, with a prevalence of 7 percent in
the U.S. and 25-30 percent in some Asian countries [2].
Lean NAFLD is caused by genetic mutations,
resulting in triglyceride accumulation in the liver [7],
http://www.jcancer.org
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or, more typically, by diet-related visceral obesity
(diet high in fructose, fat, and cholesterol). Lean
NAFLD patients differ from obese NAFLD patients in
that they do not exhibit all the co-morbidities of
metabolic diseases, such as insulin resistance, higher
serum cholesterol and triglyceride levels, or higher
liver enzymes. Lack of typical risk factors makes
identification of NAFLD in lean patients difficult, thus
increasing the likelihood of delayed diagnosis and
poor prognosis [8,9].
Lipogenesis and changes in lipid metabolism are
characteristic in NAFLD progression. Alterations in
fatty acids in the serum of NASH patients have been
reported [10,11]. Currently studies have not
addressed the progression to HCC. However, it has
been shown that various phospholipids and
ceramides are reduced in human HCC tissues
compared to adjacent tissues [12]. Furthermore,
specific patterns of serum and tissue fatty acid levels
were shown to correlate with early-stage HCC in a
genetic murine model of NASH [13] and the levels of
free fatty acids were elevated in the livers of mice with
diet-induced NAFLD [14].
Various mouse models of diet-induced HCC
have been generated. However, these mouse models
develop diet-induced HCC in the context of obesity
and/or they develop HCCs with low penetrance or
with high penetrance after a very long duration of
feeding (80 weeks) [15,16,17,18]. To date, there is no
model of lean NASH-HCC with high penetrance that
would allow further investigation into the molecular
mechanisms of this disease. To this end, we sought to
develop a lean NASH-HCC mouse model by utilizing
a choline deficient, high trans-fat/sucrose/cholesterol
diet to induce NASH-HCC in mice of the C57BL/6N
strain. We further investigated plasma and tissue
levels of fatty acids to characterize changes in lipid
metabolism during disease progression.

Materials and Methods
Animals and experimental diets
This study was conducted with the approval of
the Institutional Animal Care and Use Committee at
the University of Nebraska Medical Center (UNMC)
(Protocol #: 16-121-11). Male C57BL/6N mice (n = 50)
were obtained from Charles River Laboratories at 3
weeks of age. Upon arrival they were allowed to
acclimate for a week and at 4 weeks their diet was
switched from the standard chow diet to refined diets.
They were housed in a temperature-, humidity-, and
ventilation-controlled vivarium and kept on a 12-h
light/dark cycle under specific pathogen-free
conditions. 35 mice were fed a choline deficient, high
trans-fat, sucrose, and cholesterol diet (CD-HFSC;
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D16120210, Research Diets, New Brunswick, New
Jersey). 15 mice were fed a low-fat control diet
(D16120211, Research Diets, New Brunswick, New
Jersey) (Supplemental Table S1). Food consumption
was monitored twice a week by recording weight of
feed before and after changing feed.

Mouse health surveillance
Mice were weighed weekly and regular
husbandry checks were performed for signs of
anemia, jaundice, weight loss, and dermatitis. Mice
were euthanized if they appeared sick per
institutional guidelines. Ultrasound evaluation was
performed at 46 weeks of age using the VisualSonics
Vevo 3100 ultrasound system (Fujifilm, VisualSonics,
Toronto, ON) with the MX550D transducer (40 MHz
center frequency, 40 µM axial resolution). In brief,
mice were anesthetized using 1-3% isoflurane, placed
on a heated monitoring table, and had abdominal hair
removed. B-mode images and 3D volumes were
acquired in the abdominal area where liver nodules
were investigated. Vevo Lab software was used to
reconstruct nodule shapes and to measure nodule
volumes. Nodules that measured 1mm × 1mm were
considered false positives.

Glucose tolerance test
Intraperitoneal glucose tolerance tests (IPGTT)
were performed at 8, 20, 32, and 44 weeks of age. Five
mice from each diet group were randomly selected
and tested at 8 and 20 weeks and all mice were tested
at 32 and 44 weeks. Mice were fasted for 6 hours in the
morning, weighed and then glucose (2 g/kg) was
administered through intraperitoneal injection. Blood
samples were taken from the tail vein and glucose
levels were measured with Nova Max Plus
glucometer and test strips (Waltham, Massachusetts)
prior to glucose injection (0 minutes), and at 15, 30, 60,
and 120 minutes post glucose challenge. Glucose
levels were graphed as a function of time and the area
under the curve was calculated by the trapezoid
method [19].

Measurement of plasma lipids and liver
enzymes
Whole blood was collected from CD-HFSC mice
(n = 31) and control diet mice (n = 15) at 26 weeks of
age to assess plasma lipids (cholesterol, triglycerides)
and liver enzymes (alanine aminotransferase, ALT;
aspartate aminotransferase, AST). Approximately 300
µL of blood was collected in lithium heparin
microtubes from the mandibular vein after a 6 hour
morning fast. Blood samples were centrifuged at
13,000×g for 5 minutes at 4 °C. Plasma was aliquoted
and stored at –80 °C until processing. Approximately
100 µL of plasma was analyzed using the Vitros-250
http://www.jcancer.org
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system (Ortho-Clinical Diagnostics, Linden, New
Jersey) to measure the levels of ALT, AST,
triglycerides, and total cholesterol at the Nebraska
Center for Prevention of Obesity Diseases (NPOD)
Biomedical and Obesity Research Core (BORC) in
Lincoln, Nebraska.

Histological Evaluation
Livers were excised post mortem, weighed, and
observed grossly for the appearance of nodules. Parts
of tissues were snap frozen in liquid nitrogen and
stored at -80 °C and the remaining tissues were fixed
in 10% formalin for 2 hours and paraffin embedded
(UNMC Tissue Sciences Facilities). Tissue sections
were stained with Hematoxylin and Eosin (H&E),
Masson-Trichrome, and reticulin and were assessed
blindly by an experienced pathologist for steatosis,
ballooning, and inflammation. NAFLD and NASH
were assessed using a previously described scoring
system [20]. The stained liver sections were also
evaluated for the presence of regenerative nodules,
dysplastic nodules, and hepatocellular carcinomas.
Regenerative nodules were apparent by H&E stain,
did not compress the surrounding hepatocytes, and
had an intact reticulin network surrounding the
hepatocytes with mild cytologic atypia (cell change).
Dysplastic nodules were obvious on low power by
H&E stain, were expansile in nature, and compressed
the surrounding hepatocytes with limited destruction
of reticulin network. Nodules were classified as HCC
if they were expansile and compressed the
surrounding hepatocytes with destruction of the
reticulin framework and pseudo acinar changes
and/or cytologic atypia.

Metabolomics
Plasma collected at 32 and 55 weeks of age and
tissue collected at 55 weeks of age were analyzed for
fatty acid levels. Plasma samples were randomly
selected from mice fed the CD -HFSC diet that had
HCC (n = 5), mice with regenerative or dysplastic
nodules without HCC (pre-malignant nodules; n = 5),
and HCC-free mice fed the control diet with NAFLD
(n = 5). Five tissue samples from HCCs obtained from
the same mice were also analyzed.
Plasma (n = 30) and tissue (n = 5) samples were
prepared for analysis through dilution and
homogenization of tissue samples in a phosphate
buffer using a bead homogenizer (Precellys, Bertin
Technologies). Samples were adjusted to a final
volume of 0.5-1 mL with LC-MS grade water,
acidified with dilute hydrochloric acid and extracted
with isooctane-ethyl acetate. Extracts were then dried
and reconstituted in methanol-water-ammonium
acetate. The extracts were sent to the Lipidomics Core
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Facility at Wayne State University for fatty acid
metabolomics analysis. The extracts were subjected to
HPLC on Targa C8 column and directly introduced to
the QTRAP5500 mass analyzer (ABSCIEX). The data
were collected using Analyst 1.6.2 software and the
chromatograms were quantitated by MultiQuant
software (ABSCIEX). In total 30 fatty acids (C12-C26)
were analyzed (Supplemental Table S2).

mRNA sequencing analysis
Total RNA was extracted from liver tissue of
mice fed the control diet (2 mice with NAFL) and
those fed the CD-HFSC diet (3 mice with HCC). RNA
was isolated from approximately 10 mg of snapfrozen liver tissue using Qiagen RNeasy lipid tissue
kit (Qiagen, Cat No 74804, Germantown, MD). Purity
and concentration were assessed by measurement of
the A260/280 ratios using a Nanodrop (Thermo
Scientific, Nanodrop Products, Wilmington, DE)
spectrophotometer and only those samples with
values of 1.8 to 2.0 underwent further processing.
Samples were sent to BGI (Cambridge, MA) for
degradation testing via analysis of 200ng of RNA with
a Bioanlayzer instrument (Aligent Technologies,
Santa Clara, CA) and only intact RNA samples were
utilized to make sequencing libraries. Libraries were
sequenced using BGI’s DNBseq platform which
utilizes the BGISEQ-500 sequencing system and
provides coverage of approximately 20 million reads
per sample in 50bp single end reads. Following
sequencing bioinformatics were conducted by BGI.
Briefly, sequences were trimmed for quality control
and aligned to the mouse genome. Differential
expression was determined using RNA-Seq by
Expectation-Maximization (RSEM; https://deweylab.
github.io/RSEM/) and a false discovery rate of 
were used as significant selection criteria.

Western blotting
Tissue lysates were prepared using a standard
protein extraction protocol from 3 mice with NAFLD
(control diet fed group), 2 mice with NASH, 3 mice
with premalignant nodules and 3 mice with HCC
(CD-HFSC fed group). Equal amounts of protein (20
µg) were run on SDS-PAGE on a 4-12% Bis-Tris
NuPage Gel (ThermoFisher Scientific, Waltham, MA)
then transferred to nitrocellulose membranes and
incubated with primary antibodies: 1) 33$5ǂ
(ab24509; Abcam) DW  GLOXWLRQ DQG   ǃ-actin
HRP (#4970, Cell Signaling Technology) at 1:1000
dilution.
Membranes
were
incubated
with
appropriate
horseradish
peroxidase-conjugated
secondary antibodies (anti-rabbit, IgG #7074S; Cell
Signaling Technology). Bound antibody was
visualized on X-ray film. Membranes were stripped
http://www.jcancer.org
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using Restore Western Blot Stripping Buffer (ThermoFisher Scientific, Waltham, MA) for incubation with
the second antibody.

Statistical Analyses
Data analyses were performed using SAS 9.2
software (SAS Institute Inc, Cary, North Carolina).
Continuous data were expressed as mean +/standard deviation or as absolute number or
percentage for categorical variables. Group
comparisons were performed using a Student’s
two-tailed t-test and comparisons of AUC were
analyzed with repeated-measures ANOVA. For
differences in fatty acid levels, a one-way ANOVA
was performed and significance determined using
Tukey’s post hoc test. A p value < 0.05 was considered
statistically significant for all comparisons.

Results
Assessment of weight gain and glucose
tolerance
Mice on the CD-HFSC diet did not become obese
and gained significantly less weight than mice fed the
low-fat control diet (p = 1.74 × 10-6) (Figure 1A) even
when on average consuming the same amount of food
(p = 0.293) (Figure 1B). CD-HFSC and control mice
gained an average of 155% (+/- 32.89%) and 215%
(+/- 46.8%) of their starting weight respectively (data
not shown). Glucose tolerance was measured every 12
weeks starting at 8 weeks of age until 44 weeks. There
were no pronounced differences between mice fed the
CD-HFSC diet and mice fed the low-fat control diet
(Figure 2).

Assessment of liver damage and plasma lipid
profile
Blood was collected from mice at 26 weeks of age
to analyze liver enzymes (AST, ALT), and plasma
lipids (cholesterol and triglycerides). Plasma levels of
cholesterol were similar in mice of both diet groups;
however, triglyceride levels were lower in mice fed
the CD-HFSC diet compared to mice fed the control
diet. Cholesterol levels in both diet groups were
higher than the normal range of plasma cholesterol
(Figure 3A). Both ALT and AST liver enzyme levels
were significantly higher in mice fed the CD-HFSC
diet compared to mice fed the control diet (Figure 3B).

Assessment of NASH and HCC development
Mice fed the CD-HFSC diet had enlarged livers,
significantly higher liver to body weight ratio and
enlarged spleens compared to mice fed the control
diet. Mice fed the CD-HFSC diet developed an
average of 11 nodules with an average size of 44.20
mm2. None of the mice fed the control diet developed
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any nodules (Supplemental Table S3). Ultrasound
evaluation of 10 mice (CD-HFSC n = 5; Control n = 5)
at 46 weeks revealed nodules with an average size of
8.28 mm2 in 100% of CD-HFSC fed mice evaluated but
no nodules in mice fed the control diet (data not
shown).
Liver tissue was analyzed in all mice at time of
euthanasia. In total, 28 CD-HFSC mice (100%)
developed NASH while 7 (46.67%) normal diet mice
had normal phenotypes and 8 (53.33%) had NAFL
(Figure 4A-C). No mouse fed the control diet
developed NASH. Of the 28 CD-HFSC fed mice 13
(46.4%) had a ballooning score of 1, and 15 (53.6%)
had a ballooning score of 2 (0-2 scale). In addition, the
liver tissue was assessed for fibrosis using Trichrome
stains. In total, 14 (50%) of the 28 CD-HFSC mice had
a fibrosis score of 1, while 12 (42.8%) had a score of 2
and 2 (7.1%) had a score of 3 (Table 1). None of the
control mice had fibrosis. Regenerative, dysplastic,
and HCC nodules were also observed (Figure 4 D-F).
Mice fed the CD-HFSC diet developed HCC with high
penetrance (60.7%). In addition, 92.9% and 89.3% mice
fed the CD-HFSC diet developed regenerative
nodules and dysplastic nodules, respectively (Table
1). None of the control mice developed any type of
nodules.

Metabolic profile of fatty acids in plasma and
HCC tissues
We evaluated plasma levels of thirty fatty acids
at 32 weeks of age and the study endpoint (55-56
weeks of age) (Supplemental Table S2). At 32 weeks
11 of the 30 fatty acids were reduced significantly in
the plasma of mice fed the CD-HFSC diet (with
pre-malignant and malignant lesions) compared to
mice fed the control diet (with NAFL). 73% of those
fatty acids were polyunsaturated fatty acids (PUFAs).
At 55-56 weeks of age, 9 fatty acids were reduced
significantly in the plasma of mice fed the CD-HFSC
diet compared to mice fed the control diet. 67% of
those fatty acids were PUFAs (Supplemental Table
S4). There were no significant differences in the fatty
acid levels between mice with HCC and mice with
pre-malignant nodules; however, there was a further
reduction in the levels of these fatty acids in mice with
HCC compared to mice with pre-malignant lesions
(Figure 5). Five fatty acids were significantly reduced
in mice fed the CD-HFSC diet compared to mice fed
the control diet at both time points: OLQROHQLF DFLG ǂ
DQGǄ HLFRVDSHQWDHQRLFDFLG (3$ SDOPLWROHLFDFLG
docosahexaenoic acid (DHA), linoleic acid, and
arachidic acid (Figure 5A and B). These same fatty
acids significantly increased over time in mice with
pre-malignant lesions (Figure 5C).
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Figure 1. Weight gain and food consumption. A. Weight of mice fed the control diet (black) and the CD-HFSC diet (grey). Mice fed the CD-HFSC diet gained weight but had
lower weight compared to mice fed the control diet (P < 0.001 after week 4). B. Feed consumption was assessed per cage. Overall the two groups of mice seem to be consuming
the same amount of food. * = p < 0.05.

Table 1. Frequency of fibrosis stages 1-3, NAFL, and NASH in mice fed the control diet and mice fed the CD-HFSC diet at 55-56 weeks
of age. All mice fed the CD-HFSC diet developed NASH but none developed cirrhosis
CD-HFSC diet
Control diet

Fibrosis 1
50% (14/28)
0% (0/15)

Fibrosis 2
42.9% (12/28)
0% (0/15)

Fibrosis 3
NAFL
NASH
7.1% (2/28) 0% (0/28)
100% (28/28)
0% (0/15)
53.3% (8/15) 0% (0/15)

Regenerative Nodules
92.9% (26/28)
0% (0/15)

Dysplastic Nodules HCC
89.3% (25/28)
60.7% (17/28)
0% (0/15)
0% (0/15)

http://www.jcancer.org
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Figure 2. Glucose tolerance tests in mice fed the control diet (black) and the CD-HFSC diet (grey). Mice fed the CD-HFSC diet show no difference in glucose tolerance
compared to mice fed the control diet.

Figure 3. A. Plasma lipid and B. plasma enzyme profile in mice fed the control diet (black) and the CD-HFSC diet (grey). Mice fed the CD-HFSC diet show lower plasma
triglyceride levels and higher levels of plasma aspartate aminotransferase (AST) and alanine aminotransferase (ALT) compared to mice fed the control diet, likely reflecting lipid
retention in the liver and liver damage, respectively. Horizontal black lines indicate lower and upper limits of normal plasma lipid and enzyme levels.
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Figure 4. Mice fed the CD-HFSC diet developed NASH-HCC with high penetrance by 55-56 weeks of age. A. H&E stain of normal hepatic tissue; B. NAFL; H&E stain displaying
some fat with little inflammation or hepatocyte damage; C. NASH; H&E stain with inflammation and hepatocyte damage with fat in liver; D. regenerative nodule compressing
surrounding parenchyma with an intact reticulin network; E. H&E stain of dysplastic nodule compressing hepatocytes; F. H&E stain of HCC compressing surrounding
hepatocytes with focal destruction of reticulin framework.

Table 2. DEGs related to desaturase expression and
homocysteine levels when comparing livers with NAFLD from
control mice to HCCs from mice fed the CD-HFSC diet
Gene
Cbs
Srebf1
Scap
Mthfd1l
Fasn
Acly

Log2 fold change
-1.807900844
-2.650504371
-2.36427007
2.830242531
-3.549853812
-3.430667537

Adj P-value
6.25 × 10-6
1.39 × 10-10
9.78 × 10-10
2.25 × 10-6
6.80 × 10-10
5.87 × 10-8

Assessment of expression of genes related to
control of PUFA levels
We conducted mRNA sequencing analysis to
compare gene expression in livers of mice fed the
control diet with NAFLD and mice fed the CD-HFSC
diet with HCCs (Table 2). We found reduced levels of
genes controlling desaturase expression such as sterol
regulatory element-binding protein 1 (Srebf1), Srebp
cleavage activating protein (Scap), fatty acid synthase
(Fasn), and ATP citrate lyase (Acly) in HCCs
compared to livers with NAFLD. In addition, we
found reduced levels of genes affecting homocysteine
levels such as cystatheione beta synthase (Cbs). We
also found increased levels of Methylenetetrahydrofolate Dehydrogenase (NADP+ Dependent) 1
Like (Mthfd1l), which would result in higher levels of
tetrahydrofolate (THF). With annotation of the
differentially expressed genes (DEGs) to pathways,
we found the highest percentage of DEGs to belong to
metabolic pathways (14.6%), followed by 5.02% of
DEGs belonging to cancer pathways, and 3.93%
belonging to the PI3K-Akt signaling pathway when
comparing NAFLD with HCC.

We also assessed protein expression of PPARǂ.
PPARǂ contributes to the activation of desaturases
that are the rate-limiting enzymes for PUFA
conversion and hence are the main determinants of
PUFA levels. In addition, it is implicated in lipid
metabolism and inflammation responses. The
expression of PPARǂ was lower in the tumors of mice
fed the CD-HFSC diet and some of the pre-malignant
nodules compared to NASH tissue in CD-HFSC fed
mice and NAFLD tissue from mice fed the control diet
(Supplemental Figure 1).

Discussion
A diet deficient in choline and high in trans-fat/
cholesterol/sucrose resulted in the development of
NASH-HCC with high penetrance in lean mice. These
mice, like many lean NASH patients do not exhibit
glucose intolerance nor high levels of plasma
cholesterol and triglycerides [21]. Choline deficiency
results in triglyceride retention in the liver since it
impacts on the packaging and export of triglycerides
through VLDL from the liver [22]. These mice
exhibited higher plasma levels of liver enzymes,
indicating ongoing liver damage that is consistent
with high fat diet-induced mitochondrial lipid
metabolism, increased production of reactive oxygen
species and consequent lipotoxicity [23].
Mice with lean NASH had the key feature of
hepatocyte ballooning observed in human NASH. The
livers of all mice with NASH exhibited hepatocyte
ballooning, with 53.6% having a ballooning score of 2.
The lean NASH-HCC model developed in this work
presents several advantages to existing NASH-HCC
models. It is the first lean NASH-HCC model that
http://www.jcancer.org
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shows a high (60.7%) penetrance of HCC after the
shortest duration (52 weeks) on the experimental diet.
Another model that used a choline deficient/high fat
diet showed development of HCC in non-obese mice
with 27% penetrance after 60 weeks on the diet [17].
Other non-obese HCC models involve use of a choline
deficient diet or a choline deficient/ethionine
supplemented diet, albeit in these models mice
develop HCC after 80 weeks on the diet with 22% and
86% penetrance, respectively [18]. The other nonobese model of NASH-HCC involves pTEN gene
deletion and these mice develop HCC after 74-78
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weeks on a chow diet with 66% penetrance [13]. Other
NASH-HCC models occur in the context of obesity
and mice develop small HCCs with 60% penetrance
after 52 weeks on a high trans-fat/sucrose/fructose
diet or HCCs with 25% penetrance after 48 weeks on a
choline deficient/high sucrose/fat diet [15,16]. Of
note, the aforementioned obese NASH-HCC models
used the C57BL/6J strain, which has a polymorphism
in the Nnt gene implicated in insulin response, as
opposed the C57BL/6N strain we used in this study
[24]. We suggest that the C57BL/6N strain is ideal to
use for a lean NASH-HCC model.

Figure 5. Fatty acid levels in mice fed the CD-HFSC diet with HCC and pre-malignant (PRE) nodules, and mice with NAFLD fed the control diet (NAFLD-CON). A and B. Mice
with nodules (PRE and HCC) had significantly lower plasma levels of specific fatty acids than control mice with NAFLD at 32 and 55 weeks (* = p < 0.05). C. The levels of
polyunsaturated fatty acids increased from 32 weeks to 55 weeks in mice with premalignant nodules. Polyunsaturated fatty acids = PUFA; monounsaturated fatty acids = MUFA;
saturated fatty acids = SFA; +µg/mg.

http://www.jcancer.org
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Deregulated lipogenesis is a feature of
carcinogenesis. In our mice, mostly PUFAs showed
lower plasma levels in mice with pre-malignant and
malignant nodules compared to mice with fatty liver
fed the control diet. Furthermore, some of these
PUFAs increased over time in mice with
pre-malignant nodules, suggesting they may be
important for cancer inhibition. These PUFAs
included linolenic acids (ǂ DQG Ǆ ǚ-3and ǚ-6,
respectively), EPA (ǚ-3), DHA (ǚ-3), and linoleic acid
(ǚ-6). These PUFAs have been previously shown to be
involved in livHU FDUFLQRJHQHVLV )RU H[DPSOH Ǆ
linolenic acid has been shown to reduce cell
proliferation and promote the generation of ROS and
apoptosis in HCC cell lines [25]. Furthermore, it had a
chemo-protective effect against diethylnitrosamineinduced HCCs [26]. EPA- and DHA-enriched diet fed
mice were shown to be metabolically healthier with
lower lipid and fatty acid biosynthesis as well as
upregulation of PPARǂ and lipid catabolism [27]. In
our mice, lower plasma levels of these fatty acids
occurred with tumor progression and lower levels of
PPARǂ in the tumors (Supplemental Figure 1).
Linoleic acid was the only fatty acid that was
significantly reduced in human HCC tissue in a tissue
metabolomics investigation of human HCC [28].
Furthermore, a mouse model of NASH-HCC using
mice with hepatocyte deletion of pTen also revealed
reducWLRQ LQ OLQROHLF DQG Ǆ-linolenic acids in plasma
and NASH tissue and further reduction of linoleic
acid in HCC tissue [13].
One possible mechanism for lower PUFA
production in our mice may be lower expression of
PPARǂ in pre-malignant and HCC tissues, which may
contribute to higher levels of inflammation and
reduced production of PUFAs by desaturases
(Supplemental Figure 1). More specifically,
PPARǂhas been shown to be involved in the control
RIWKHGHVDWXUDVHV ƦDQGƦ6) in the liver that affect
the production of these PUFAs [29]. Furthermore,
mRNA sequencing analysis revealed lower
expression of genes implicated in desaturase
expression such as Srebf1, Scap, Fasn, and Acly in
HCCs compared to livers with NAFLD. This suggests
that the production of PUFAs is suppressed by
changes in gene expression during tumor
progression. Interestingly, genes implicated in homocysteine metabolism such as Cbs were also downregulated in HCCs compared to NAFLD, which could
result in higher homocysteine levels. PUFAs have
been shown to modulate homocysteine levels,
whereby PUFA supplementation results in reduction
of homocysteine levels [30-32]. This data suggests that
reduction of PUFAs along with increase in
homocysteine levels may be contributing to lean
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NASH-HCC progression. Elevated homocysteine
levels have been previously suggested to promote
hepatocarcinogenesis [33]. EPA and DHA, which
were reduced in our HCC–bearing mice, are
considered to be the biosynthetic precursors of potent
anti-inflammatory mediators such as resolvins and
protectins, suggesting that their reduction may be
permissive of a tumor-promoting inflammatory
environment. Resolvin E (RvE) and resolvin D (RvD)
series of resolvins are derived from EPA and DHA.
Interestingly, resolvin D1 and resolving E1 were
found to prevent liver injury and the progression
from hepatitis to liver cancer through inhibition of
NFNB in mice [34]. Furthermore, resolvin D1 was
shown to prevent epithelial mesenchymal transition
and cancer stemness in HCC [35]. Further supporting
the link between PUFAs and inflammation, omega 3
PUFAs such as EPA and DHA have been shown to
inhibit hepatocellular carcinoma cell growth by
blocking inflammation mediators such as cyclooxygenase 2 (COX-2) [36].
Another observation from our mRNA
sequencing analyses was that DEGs that belong to
metabolic pathways were the most frequent (14.6%),
followed by 5.02% of DEGs belonging to cancer
pathways, and 3.93% belonging to the PI3K-Akt
signaling pathway when comparing NAFLD with
HCC. Interestingly, the PI3K-Akt signaling pathway
has been linked to liver inflammation in HCC [37].
Therefore, it is plausible that reduction of PUFAs may
be contributing to increased inflammation in a PI3KAkt pathway and NFNB dependent manner. On a final
note, we also found increased levels of Mthfd1l,
which would result in higher levels of THF. We
suggest that increased production of THF would not
be used for homocysteine remethylation but rather be
used for nucleotide synthesis to support tumor cell
proliferation. This would also contribute to the
accumulation of homocysteine.
In conclusion, we present a novel lean NASHHCC model using the C57BL/6N strain that shows
high penetrance of HCC after 52 weeks on a choline
deficient and high trans-fat/sucrose/cholesterol diet.
Furthermore, our study shows for the first time that
certain PUFAs (linolenic acids (ǂ DQGǄǚ-and ǚ-6,
respectively), eicosapentanoic acid (ǚ-3), docosahexanoic acid (ǚ-3), and linoleic acid (ǚ-6)) show
reduced levels in lean NASH-HCCs and increasing
levels in mice with pre-malignant lesions suggesting
their anti-carcinogenic properties. We suggest further
study of the mechanisms driving lower PUFA levels
as well as the molecular and cellular consequences of
lower PUFA production. We also suggest to consider
using PUFA supplementation as a way to inhibit HCC
formation and PUFA levels as potentially biomarkers
http://www.jcancer.org
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for lean NASH-HCC. This has been suggested for
colorectal cancer (CRC). A meta-analysis and
systematic review of CRC and blood PUFA levels has
shown that high blood n-3 PUFA levels are inversely
associated with colorectal cancer risk and high intake
of these PUFAs has been found to be associated with
lower colorectal cancer risk [38]. Finally, consumption
of n-3 fatty acids has been shown to be inversely
associated with HCC in a population-based
prospective cohort study of Japanese individuals [39].
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